Global GLP-1 Peptide Drugs Market Growth (Status and Outlook) 2024-2030

Global GLP-1 Peptide Drugs Market Growth (Status and Outlook) 2024-2030

Glucagon-likepeptide-1 (GLP-1) is a hormone secreted by intestinal L cells. Its receptor (GLP-1R) is widely distributed in the central nervous system, cardiovascular system, muscles, and gastrointestinal tract. multiple organs and tissues. GLP-1 has glucose concentration-dependent hypoglycemic effects, and its receptor agonist (GLP-1RA) can simulate the physiological effects of GLP-1 and is an important drug for the treatment of diabetes and obesity. In addition, GLP-1RA also has protective effects on the cardiovascular system, kidneys, central nervous system, etc.

GLP-1 peptide drugs are often used to treat patients with type 2 diabetes. They can control blood sugar while also bringing weight loss and reducing cardiovascular risk.

The global GLP-1 Peptide Drugs market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “GLP-1 Peptide Drugs Industry Forecast” looks at past sales and reviews total world GLP-1 Peptide Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected GLP-1 Peptide Drugs sales for 2023 through 2029. With GLP-1 Peptide Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GLP-1 Peptide Drugs industry.

This Insight Report provides a comprehensive analysis of the global GLP-1 Peptide Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on GLP-1 Peptide Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global GLP-1 Peptide Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GLP-1 Peptide Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GLP-1 Peptide Drugs.

United States market for GLP-1 Peptide Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for GLP-1 Peptide Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for GLP-1 Peptide Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key GLP-1 Peptide Drugs players cover AstraZeneca, Novo Nordisk, Sanofi, GSK, Eli Lilly, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of GLP-1 Peptide Drugs market by product type, application, key players and key regions and countries.

Segmentation by Type:
Injection
Oral

Segmentation by Application:
Type 2 Diabetes
Obesity
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Injection
Oral

Segmentation by Application:
Type 2 Diabetes
Obesity
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Novo Nordisk
Sanofi
GSK
Eli Lilly
Benemae Pharmaceutical
Hansoh Pharmaceutical

Please note: The report will take approximately 2 business days to prepare and deliver.